BACKGROUND There is no randomized clinical trials with recurrence of atherosclerotic cardiovascular disease (ASCVD) as a major outcome with rosuvastatin. In order to analyze potential differences in the clinical response to atorvastatin and rosuvastatin in secondary ASCVD prevention, we have analyzed the clinical evolution of those subjects of the Dyslipemia Registry of the Spanish Society of Arteriosclerosis (SEA) who at the time of inclusion in the Registry had already suffered an ASCVD. METHODS This observational, retrospective, multicenter, national study was designed to determine potential differences between the use of atorvastatin and rosuvastatin in the ASCVD recurrence. Three different follow-up start-times were performed: time of inclusion in the registry; time of first event if this occurred after 2005, and time of first event without date restriction. RESULTS Baseline characteristics were similar between treatment groups. Among atorvastatin or rosuvastatin users, 89 recurrences of ASCVD were recorded (21.9%), of which 85.4% were coronary. At the inclusion of the subject in the registry, 345 participants had not suffered a recurrence yet. These 345 subjects accumulated 1050 person-years in a mean follow-up of 3 years. Event rates were 2.73 (95% CI: 1.63, 4.25) cases/100 person-years and 2.34 (95% CI: 1.17, 4.10) cases/100 person-years in the atorvastatin and rosuvastatin groups, respectively. There were no statistically significant differences between the two groups independently of the follow-up start-time. CONCLUSIONS This study does not find differences between high doses of rosuvastatin and atorvastatin in the recurrence of ASCVD, and supports their use as clinically equivalent in secondary prevention of ASCVD.

中文翻译：

---

阿托伐他汀和瑞舒伐他汀在预防心血管疾病复发中的比较疗效。

背景技术目前尚无关于瑞舒伐他汀作为主要结果复发的动脉粥样硬化性心血管疾病（ASCVD）复发的随机临床试验。为了分析在继发性ASCVD预防中对阿托伐他汀和瑞舒伐他汀的临床反应的潜在差异，我们分析了西班牙动脉硬化学会（SEA）血脂异常登记册中纳入登记册时那些受试者的临床演变已经患有ASCVD。方法这项观察性，回顾性，多中心，全国性研究旨在确定在ASCVD复发中使用阿托伐他汀和瑞舒伐他汀之间的潜在差异。进行了三种不同的随访开始时间：纳入注册表的时间；第一次事件发生的时间（如果发生在2005年之后），没有日期限制的第一次活动的时间和时间。结果治疗组之间的基线特征相似。在使用阿托伐他汀或瑞舒伐他汀的患者中，记录了89例ASCVD复发（21.9％），其中85.4％为冠状动脉。将该主题纳入注册表后，有345名参与者尚未复发。这345名受试者的平均随访时间为3年，累积了1050人年。阿托伐他汀组和罗苏伐他汀组的事件发生率分别为2.73（95％CI：1.63，4.25）例/ 100人年/年和2.34（95％CI：1.17，4.10）例/ 100人年。独立于随访开始时间，两组之间在统计学上无显着差异。结论本研究未发现大剂量瑞舒伐他汀和阿托伐他汀在ASCVD复发中的差异，